Načítá se...
Glucagon‐like peptide‐1 receptor agonists in the era of COVID‐19: Friend or foe?
The aim of the present manuscript is to discuss on potential pros and cons of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) as glucose‐lowering agents during COVID‐19 pandemic, and what is more to evaluate them as potential candidates for the treatment of patients, affected by COVID‐19 infect...
Uloženo v:
| Vydáno v: | Clin Obes |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Blackwell Publishing Ltd
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7995087/ https://ncbi.nlm.nih.gov/pubmed/33423388 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cob.12439 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|